The hormonal condition affecting 1 in 8 women worldwide, formerly known as polycystic ovary syndrome (PCOS), has been renamed polyendocrine metabolic ovarian syndrome (PMOS), according to reports. The change aims to correct the misconception that the disorder is solely a gynecological disease characterized by ovarian cysts.
PCOS has long been understood as a condition involving irregular menstrual cycles, excess androgen levels, and polycystic ovaries. However, medical experts have increasingly recognized that it encompasses metabolic and endocrine dysfunctions beyond reproduction. The new name, PMOS, highlights the polyendocrine and metabolic nature of the syndrome.
The Guardian reported that the relabeling is intended to correct the misconception that it is solely a gynecological disease that creates ovarian cysts. Time magazine noted that medical care for the condition has typically focused on fertility and reproduction, at the expense of the other effects of the disorder. This emphasis on metabolic and endocrine aspects is seen as a step toward more comprehensive care.
The Washington Times stated that the name change comes in hopes of improving care for the condition, which affects 1 in 8 women globally. The outlet highlighted that the new name, polyendocrine metabolic ovarian syndrome, reflects a broader understanding of the disorder.
The renaming is being adopted to guide future research and treatment approaches, encouraging healthcare providers to address the full spectrum of symptoms, including insulin resistance, obesity, and cardiovascular risks, alongside reproductive health.
閱讀原始報道
💬 评论
📜 评论政策